Usefulness of FFR in coronary bypass intermediate lesions

Original title: Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. Reference: Luigi Di Serafino et al. Am Heart J 2013;166:110-8.

Bypass coronary angioplasty is often preferred strategy versus re-operation , however it is associated with a greater number of events,  both short and long term, compared to native vessels angioplasty. The procedure is usually more difficult given the high amount of patient comorbidities and complexity of lesions so it is crucial to counterbalance the cost / benefit, especially in intermediate lesions .

The fractional flow reserve ( FFR ) has been shown to improve outcomes in native arteries but, so far there is no evidence to use it in coronary bypass. Intermediate lesions were considered those with a stenosis degree between 40% and 70% by visual estimation. We excluded patients with bypass tandem lesions, distal to the anastomosis native artery lesions and sequential bypass .

FFR branch guided patients received angioplasty only if FFR was ≤ 0.8. In total 223 patients were registered, of which 65  received FFR and 158  were guided by angiography. The injury rate in the FFR group has been more frequent in arterial bypasses and severity of intermediate lesions was higher in the angiography guided group.

In the FFR group , 23 patients ( 35 % ) received angioplasty (FFR 0.68 ± 0.09 ) and the rest, optimal medical treatment (FFR 0.92 ± 0.05, p = 0.01 versus those receiving angioplasty). In the angiography guided group , 90 patients ( 57 % ) underwent angioplasty ( % stenosis by quantitative angiography 56.8 ± 13.7 ) and the rest, medical treatment ( % stenosis by quantitative angiography 41.7 ± 9, p = 0.01 versus those receiving angioplasty). The FFR group received significantly fewer stents than the group guided by angiography. At follow-up at 3.8 years, FFR -guided group showed a lower rate of combined events (death, MI , stroke , revascularization ) than the angiographic group ( 28 versus 51% , HR 0.46, CI 0.28 – 0.77, P = 0.003 ) . This difference remained after making an adjustment using propensity score. The advantage of the FFR was primarily in the arterial bypass since the only saphenous vein bypass was considered, no differences were observed between groups.

Conclusion:

The FFR – guided revascularization in patients with prior CABG and arterial bypasses intermediate lesions resulted in better clinical outcomes compared to angiography guided . For intermediate vein graft lesions the results were similar between the two strategies .

Editorial Comment:

 

In the group guided by angiography venous grafts were significantly treated and these consecutively had lesions (whereas entering the intermediate definition ) with a greater percentage of stenosis to the group guided by FFR . This point could only explain the difference in events. 

SOLACI.ORG

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...